What is Ametek's gross profit margin?

What were the key takeaways from Ametek’s earnings call?

Did Ametek beat or miss consensus estimates last quarter?

What were the key takeaways from Ametek's earnings call?

What factors drove the changes in Ametek's revenue and profit?

What is the market's earnings forecast for Ametek next quarter?

What is Ametek's latest dividend and current dividend yield?

What guidance did Ametek's management provide for the next earnings period?

- **Q4 Records Across the Board**: Sales, orders, EPS, and free cash flow all hit new highs.
- **Acquisition-Driven Growth**: 2025 M&A spend of $1.8B positions for 2026 MedTech expansion.
- **Strong Margins and Cash Flow**: Core margins expanded 100bps to 27.6%, free cash flow conversion 132% in Q4.
- **2026 Outlook**: Mid-single-digit organic growth, EPS up 6%-9%, with Q1 sales +10% YoY.

**【CEO Summary Section】**
- **Record Q4 Performance**: Sales of $2 billion (+13% YoY), orders up 18% to $2 billion, and EPS of $2.01 (+7% YoY). Backlog reached $3.58 billion.
- **Acquisition Strategy**: Announced LKC Technologies acquisition to expand MedTech presence. 2025 M&A spend: $1.8 billion, including FARO and Kern Microtechnik.
- **Segment Growth**: 
  - **EIG**: Sales $1.37B (+13% YoY), core margins 32.3%.
  - **EMG**: Sales $629M (+15% YoY), core margins 22.7%.
- **2026 Outlook**: Sales +mid-single digits organically, EPS $7.87-$8.07 (+6%-9%). Q1 guidance: sales +10%, EPS $1.85-$1.90.
- **Investments**: $100M+ in R&D, sales/marketing, and digital initiatives. Vitality Index at 30% (new product sales).

**【CFO Financial Commentary】**
- **Q4 Financials**: 
  - GAAP EPS: $2.01 (record), Non-GAAP EPS: $1.90-$1.95 guidance exceeded.
  - Free cash flow: $527M (132% of net income), full year $1.7B.
  - Tax rate: 16.3% (Q4), guided 18.5%-19.5% for 2026.
- **Balance Sheet**: Debt $2.3B, cash $458M. Gross debt/EBITDA: 1x, net debt/EBITDA: 0.8x.
- **2026 Guidance**: Free cash flow conversion 110%-115%. Capital expenditures: $160M (2% of sales).

AMETEK, Inc. (AME) Q4 2025 Earnings Call Transcript

- **Record Q3 Growth**: Sales $1.89B (+11%), orders $1.97B (+13%), with EBITDA margins 31.3%. EMG margins hit 25.4%, up 250 bps.
- **Strategic Investments Paying Off**: $90M in R&D/digital initiatives drive new products like AI inspection cameras and data center UPS systems.
- **M&A Pipeline Active**: $2B+ capacity to pursue deals in process, power, and automation. FARO integration on track, with $25M+ data center backlog.
- **Guidance Raised**: Full-year EPS $7.32-$7.37 (prev. $7.06-$7.20), Q4 EPS $1.90-$1.95 (+2%-4% YoY).
- **Risk Management**: Proactive trade strategies mitigate China tariff delays, with U.S./Europe sales offsetting Asia weakness.

**CEO Summary Section**
- **Record Third Quarter Performance**: AMETEK reported record sales of $1.89 billion, up 11% year-over-year, driven by 4% organic growth, 6% from acquisitions, and a 1% FX benefit. Orders reached $1.97 billion, up 13%, with a record backlog of $3.54 billion.
- **Margin Expansion**: Operating income rose 11% to $496 million, with adjusted margins at 27% (up 90 basis points). EBITDA was $592 million, up 11%, and EBITDA margins reached 31.3%.
- **Business Group Highlights**: 
  - **EIG**: Sales of $1.25 billion (+10%), operating income $360 million (+6%), and margins 30.4% (up 50 bps). New AI-powered inspection systems and defense solutions drove growth.
  - **EMG**: Sales of $646 million (+13%), operating income $164 million (+25%), with margins 25.4% (up 250 bps). Automation and aerospace demand fueled performance.
- **Strategic Initiatives**: $90 million invested in R&D, sales, and digital marketing. New products like Vertech’s AI inspection camera and NSI’s Vector Digital Receiver showcased innovation.
- **Global Trade Management**: Proactive strategies, including targeted pricing and supply chain adjustments, mitigated trade risks. U.S. manufacturing flexibility supported global customers.
- **2025 Guidance Update**: Full-year EPS raised to $7.32-$7.37 (prev. $7.06-$7.20). Q4 EPS expected $1.90-$1.95, up 2%-4% YoY.

**CFO Financial Commentary**
- **Financial Strength**: Free cash flow conversion 113%, with $420 million free cash flow. Debt-to-EBITDA ratio 0.9x, supporting $2 billion+ M&A pipeline.
- **Tax Efficiency**: Effective tax rate 17.2%, down from 18.8% YoY. Full-year rate expected 18%-18.5%.
- **Capital Deployment**: $920 million spent on FARO acquisition, $150 million share buybacks, and $71 million dividends, maintaining financial flexibility.

**Q&A Highlights**
- **Automation Recovery**: EMG orders up 13%, driven by aerospace and medical device demand. Automation business destocking completed, with Q4 orders strong.
- **M&A Pipeline**: Active in process, power, and automation markets. FARO integration progressing well, with $25 million+ backlog in data center UPS systems.
- **China Trade Dynamics**: Tariff renegotiations causing delays, but U.S. and European sales offsetting Asia weakness. Paragon Medical margins improving to 35%+.
- **A&D Growth**: High single-digit organic growth, balanced across commercial OEM, aftermarket, and defense. FARO not part of A&D, but aerospace and defense businesses winning new programs.
- **Cash Flow Utilization**: Share buybacks and dividends prioritized, with $150 million+ returned to shareholders Q3. No dividend hikes planned, focusing on M&A and growth.


AMETEK, Inc. (AME) Q3 2025 Earnings Call Transcript

- **Q2 Growth**: Revenue $1.78B (+2.5% YoY), EPS $1.78 (+7% YoY), driven by EMG margin expansion (260 bps) and FARO acquisition.
- **Segment Strength**: EMG sales +6% YoY, EIG core margin 30.7%. Automation orders up double digits, Paragon margins aligning with AMETEK.
- **FARO Synergies**: $340M EBITDA, 60% recurring revenue. Target 30% EBITDA margin in 3 years, adding 2-3 cents EPS in 2025.
- **Financial Health**: Free cash flow $330M (Q2), debt/EBITDA 0.6x. 2025 EPS guidance $7.06-$7.20 (+3%-5% YoY).
- **M&A Momentum**: $1B deployed in 2025, pipeline strong. Focus on high-margin, recurring-revenue businesses.

**【CEO Summary Section】**
- **Record Q2 Results**: Revenue of $1.78 billion (+2.5% YoY), EBITDA of $565 million (+4% YoY), and EPS of $1.78 (+7% YoY). Organic sales were flat, with acquisitions and FX contributing 1.5% and 1% growth, respectively.
- **Segment Performance**: 
  - **Electronic Instruments Group (EIG)**: Sales $1.16 billion (+1% YoY), operating margin 29.7% (core margin 30.7%).
  - **Electromechanical Group (EMG)**: Record sales $618 million (+6% YoY), operating margin 23.3% (core margin 260 bps improvement). Paragon and Automation businesses drove orders growth.
- **Strategic Acquisitions**: FARO Technologies ($920M) complements metrology capabilities, with EBITDA of $340M and recurring revenue from services/subscriptions. Expected 2-3 cents EPS contribution in 2025.
- **Tariff Mitigation**: Strong execution of pricing, supply chain adjustments, and localization reduced direct tariff impacts. Full-year organic growth guided at mid-single digits.
- **2025 Guidance**: Sales up mid-single digits, EPS $7.06-$7.20 (+3%-5% YoY). Q3 EPS $1.72-$1.76 (+4%-6% YoY).

**【CFO Financial Commentary】**
- **Profitability**: Operating income $462 million (+3% YoY), core margin 26.7% (up 90 bps). EBITDA margin 31.8%, highest in 10 years.
- **Cash Flow**: Free cash flow $330 million (Q2), 102% of net income YTD. Full-year free cash flow conversion expected at 115% of net income.
- **Balance Sheet**: Debt $1.9 billion (down $200M YoY), net debt/EBITDA 0.6x. Pro forma for FARO, gross debt/EBITDA 1.25x. $2 billion+ cash and credit facilities for M&A.
- **Tax Rate**: 19% Q2, guided 19%-19.5% for 2025. U.S. manufacturing benefits from tax reconciliation bill.

**【Q&A Highlights】**
- **End Market Trends**: 
  - **Aerospace & Defense**: Organic sales +high-single digits (up from mid-single), driven by commercial OEM.
  - **Automation**: Orders growth, destock complete, EBITDA margins aligning with AMETEK.
  - **China Metrology**: Sales down low-single digits, but pipeline strong. FARO's digital reality solutions offset macro weakness.
- **FARO Integration**: Target 30% EBITDA margin in 3 years (vs. current 15%). Synergies include cost reduction, service expansion, and SaaS growth.
- **M&A Pipeline**: $1 billion deployed in 2025, pipeline robust. Focus on $50-200M deals in attractive growth markets.
- **Tariff Impact**: $100M headwind offset by pricing, localization, and supply chain changes. 2025 organic growth assumes mid-single digits despite macro uncertainty.


AMETEK, Inc. (AME) Q2 2025 Earnings Call Transcript

- **Q1 Strong Execution**: Flat revenue but 7% EPS growth, 26.3% operating margin, $394M free cash flow. 
- **Medical Recovery**: Paragon Medical orders +25% Q/Q, leading EMG margin expansion to 21.9%. 
- **Tariff Mitigation**: $100M direct impact offset via pricing, localization. Q2 China-U.S. delays ($70M) but confident in annual guidance. 
- **A&D Growth**: Aerospace +mid-single digits, Defense stable. 
- **M&A Opportunity**: Active pipeline with $1.25B buyback authorization. 
- **Cash Flow Strength**: 112% free cash flow conversion, targeting 115% annually. 
- **Dividend Growth**: 6th consecutive year of 10%+ dividend increases.

**【CEO Opening Remarks】**
- Q1 2025 revenue: $1.73 billion (flat vs. Q1 2024), with organic sales down 1% but strong order growth (+8% overall, +3% organic). 
- Operating income: $455 million (+2%), operating margin 26.3% (+60bps). EBITDA: $559 million (+3%), EBITDA margin 32.2%. 
- Free cash flow: $394 million (112% of net income). Diluted EPS: $1.75 (+7%).
- Key business highlights:
  - **Electronic Instruments Group (EIG)**: $1.14 billion in sales, 31% operating margin (+50bps). 
  - **Electromechanical Group (EMG)**: Record $588.3 million in sales (+2%), 21.9% operating margin (+120bps). 
- New product launches (e.g., Gatan Elite Ultra, Vision Research Phantom KT-series) driving 26% Vitality Index. 
- Full year guidance: Low-single-digit sales growth, EPS $7.02-$7.18 (+3%-5%).
- Tariff mitigation plan: $100M direct impact offset via pricing, localization, productivity. China-U.S. trade conflict causing $70M Q2 shipment delays but confident in annual guidance.

**【CFO Financial Details】**
- GAAP net income: $420 million. Non-GAAP EPS: $1.75 (vs. guidance $1.67-$1.69). 
- Free cash flow conversion: 112% in Q1, targeting 115% annually. 
- Capital deployment: $1.25B share buyback authorization, 6th consecutive year of dividend increases (11% to $0.31/share). 
- Debt: $1.9B (down from $2.1B at year-end), net debt/EBITDA 0.7x. 
- 2025 capex: $155M (2% of sales), focused on R&D and digital initiatives. 
- Depreciation/amortization: $410M annualized, including $203M after-tax intangible amortization.

**【Q&A Key Takeaways】**
- **Medical Business Strength**: Paragon Medical orders up >25% Q/Q, leading EMG's 7% margin expansion. Destocking complete, 2H25 growth expected. 
- **Tariff Impact**: 145% China-U.S. tariffs affecting $70M Q2 shipments, but 98% USMCA compliant. Long-term localization plans to mitigate. 
- **A&D Growth**: Aerospace +mid-single digits, driven by commercial OEM and aftermarket. Defense funding stable. 
- **M&A Pipeline**: Active with $1.25B buyback authorization, targeting essential mission-critical businesses. 
- **China Exposure**: 9% of sales (4% direct U.S. exports), limited supply chain reliance post-2018 diversification. 
- **2025 Outlook**: Offset $100M tariffs via pricing (+2%), localization, productivity. Free cash flow to support M&A and buybacks.

AMETEK (AME)-1 May 25-2025 Q1 Earnings call transcript

- **Record Q4 Performance**: $1.76B sales, $1.87 EPS (11% YoY), 26.6% operating margin. Full-year EPS $6.83 (+7%). 
- **Cash Machine**: $498M free cash flow (129% of net income), $1.7B annual total. 
- **2025 Growth**: Low single-digit sales, $7.02-$7.18 EPS (+3-5%). Q1 flat sales, $1.67-$1.69 EPS. 
- **Acquisition Strategy**: €105M Current Micro technique adds precision manufacturing. $2.5B M&A capacity. 
- **Margin Resilience**: 31.9% EBITDA margin, 120bps core margin expansion. 2025 pricing offsets 1.5-2% inflation. 
- **Order Momentum**: Q4 orders +4%, Paragon +20%. 2025 EMG organic growth to accelerate. 
- **Geographic Shift**: 2024 international growth (+2%), 2025 balanced global expansion. 
- **Innovation Edge**: 28% vitality index, $85M R&D driving new product pipeline. 


**【CEO Summary Section】**
- **Record Financial Performance**: Q4 sales of $1.76B (+2% YoY), operating income of $469M (+5% YoY), and EPS of $1.87 (+11% YoY). Full-year sales of $6.94B (+5% YoY), EPS of $6.83 (+7% YoY). 
- **Margin Expansion**: Operating margin 26.6% (+90bps YoY), EBITDA margin 31.9%. Free cash flow of $498M (Q4 record), 129% of net income.
- **Acquisition Activity**: $155M share buybacks in Q4, $220M annual total. Post-Q4 acquired Current Micro technique for €105M to expand precision manufacturing capabilities.
- **2025 Outlook**: Low single-digit organic sales growth, EPS guidance $7.02-$7.18 (+3-5% YoY). Q1 flat sales vs. prior year, EPS $1.67-$1.69 (+23% YoY). 

**【CFO Financial Commentary】**
- **Profitability**: GAAP net income $469M, non-GAAP EPS $1.87. Effective tax rate 12.8% (Q4) vs. 17.8% prior year. Full-year tax rate 17.3%.
- **Cash Flow**: Free cash flow $1.7B (+6% YoY), 124% of net income. 2025 free cash flow conversion target 115%.
- **Balance Sheet**: Total debt $2.1B, cash $374M. Gross debt/EBITDA 0.9x, net 0.8x. $2.5B available for M&A.
- **Cost Management**: G&A 1.5% of sales. 2025 capex $155M, D&A $400M (+$194M after-tax intangible amortization). 

**【Key Q&A Insights】**
- **Order Trends**: Q4 organic orders +4% (EIG +3%, EMG +5%). Paragon orders +20% YoY, destocking easing. 2025 EMG organic growth to outpace EIG. 
- **Margin Dynamics**: 2024 core margin +120bps YoY. 2025 pricing offsetting 1.5-2% inflation. EMG automation margins poised to recover as destocking ends. 
- **Macro Resilience**: AMETEK's niche, high-margin model (31.9% EBITDA margin) insulated from macro weakness. 2025 guidance assumes no demand destruction from trade policy. 
- **Geographic Mix**: 2024 international growth (+2%) offset U.S. decline. 2025 expects balanced global expansion with strength in Asia-Pacific. 
- **Innovation Pipeline**: $85M 2025 R&D investment (2/3 in EIG) driving 28% vitality index (new products >20% revenue). CAMECA LEAP 6000 XR expands semiconductor/materials science applications. 


AME

AME fundamentals

Earnings Call

You can ask Aime